Table 3.
List From Published Literature on the Use of Dermoscopy for Posttreatment Improvement Evaluation in Some Skin and Appendageal Disorders [30–42]
| Condition | Treatment Administered or Evaluated | Remarks |
|---|---|---|
| Melasma | 1,064-nm Q-switched Nd:YAG (QSNY) laser vs QSNY + pulsed-dye laser (PDL) | |
| 17 patients (split-face study) | ||
| Actinic keratosis | Ingenol mebutate 0.015% gel | 52 patients |
| Seborrheic keratosis | Novel aqueous solution containing nitric acid, zinc and copper salts, and organic acids | 15 patients with 50 seborrheic keratoses |
| Male androgenetic alopecia | Platelet-rich plasma therapy + microneedling | 20 patients |
| Pigmented basal cell carcinoma | Imiquimod 5% cream | 20 lesions |
| Plaque psoriasis | Biological therapy: any of the 4 agents (adalimumab, etanercept, infliximab, and ustekinumab) | 75 patients |
| Verrucous epidermal nevus | Pulsed CO2 laser vs erbium:YAG laser | 20 patients (10 in each group) |
| Bowen disease | Imiquimod 5% cream OR photodynamic therapy | 23 patients with 29 lesions |
| Vulvar lichen sclerosus | Mometasone furoate 0.1% ointment + tretinoin 0.05% cream in short-contact therapy (group A) vs mometasone furoate 0.1% + emollient (group B) | 32 patients |
| Vitiligo (localized) | Combination therapy of tacrolimus ointment + 308-nm excimer laser | 147 patients |
| Axillary hair removal | Diode laser vs intense pulsed light (IPL) | 21 patients (split-half protocol) |
| Facial/upper limb telangiectasias associated with systemic sclerosis | PDL vs IPL | 19 patients (split-half protocol) |
| Scabies | Foam containing 0.165% pyrethrins and 1.65% piperonyl butoxide | 20 patients |